Literature DB >> 6861888

Differential effects of acute and chronic administration of haloperidol on homovanillic acid levels in discrete dopaminergic areas of rat brain.

T Matsumoto, H Uchimura, M Hirano, J S Kim, H Yokoo, M Shimomura, T Nakahara, K Inoue, K Oomagari.   

Abstract

After acute administration of haloperidol, homovanillic acid (HVA) levels were increased in the prefrontal cortex, anterior cingulate cortex, discrete limbic areas and A14 dopamine (DA) neurons. The maximal effect of haloperidol was attained more slowly in the prefrontal cortex and amygdala than in the other regions. The ED50 of haloperidol was 0.03 mg/kg in the prefrontal cortex, but was 0.06-0.07 mg/kg in other areas examined. After repeated administration of haloperidol, tolerance to the HVA increase was observed in the striatum and all limbic areas examined, the amygdala being the most susceptible to this tolerance. In contrast, no tolerance was found in the anteromedial and suprarhinal DA neurons of the prefrontal cortex and A14 DA neurons. These results suggest that the prefrontal cortex may be a possible site for the antipsychotic action of haloperidol. On the other hand, no change of HVA levels in the A12 and A13 DA neurons of the hypothalamus was observed after haloperidol treatments, suggesting a lack of neuronal feedback mechanism in the A12 and A13 DA neurons.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861888     DOI: 10.1016/0014-2999(83)90604-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  Regulatory aspects of nigrostriatal dopaminergic neurons.

Authors:  P Miu; F Karoum; G Toffano; J W Commissiong
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

2.  Postnatal iron-induced motor behaviour alterations following chronic neuroleptic administration in mice.

Authors:  A Fredriksson; P Eriksson; T Archer
Journal:  J Neural Transm (Vienna)       Date:  2005-08-05       Impact factor: 3.575

3.  Functional consequences of iron overload in catecholaminergic interactions: the Youdim factor.

Authors:  Trevor Archer; Anders Fredriksson
Journal:  Neurochem Res       Date:  2007-08-12       Impact factor: 3.996

4.  Dose-response curves of homovanillic acid in pre-frontal cortex and caudate following antipsychotic drugs: relation to clinical potencies.

Authors:  W H Chang; T Y Chen; H S Wu; W H Hu; E K Yeh
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Time-response curves of homovanillic acid in caudate and pre-frontal cortex following acute neuroleptic administration.

Authors:  W H Chang; T Y Chen; E K Yeh
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  Sensitization versus tolerance to the dopamine turnover-elevating effects of haloperidol: the effect of regular/intermittent dosing.

Authors:  J G Csernansky; E P Bellows; D E Barnes; L Lombrozo
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Effects of ceruletide on the dopamine receptor-adenylate cyclase system in striatum and frontal cortex of rats chronically treated with haloperidol.

Authors:  Y Hatta; S Hatta; T Saito
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Homovanillic acid in caudate and pre-frontal cortex following acute and chronic neuroleptic administration.

Authors:  M B Bowers; F J Hoffman
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

9.  Effects of a single haloperidol application to neonatal and early postnatal rats on the neurotransmitter content in the corpus striatum.

Authors:  R Schwabe; R Thiel; I Chahoud; D Neubert
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

10.  Chronic haloperidol administration increases the density of D2 dopamine receptors in the medial prefrontal cortex of the rat.

Authors:  A J MacLennan; S Atmadja; N Lee; H C Fibiger
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.